Inventor
SHANKAR BANDARPALLE B
US31 patents
⚠️ This page may combine multiple inventors who share the name “SHANKAR BANDARPALLE B”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
SCHERING CORP
25 patentsUS5856473AJan 5, 1999
Process for preparing 1-(4-fluorophenyl)-3(R)-(3(S)-hydroxy-3-( phenyl or 4-fluorophenyl!)-propyl)-4(S)-(4-hydroxyphenyl)-2-azetidinone
SCHERING CORP98 citations98
US5688960ANov 18, 1997
Substituted oximes, hydrazones and olefins useful as neurokinin antagonists
SCHERING CORP69 citations96
US5696267ADec 9, 1997
Substituted oximes, hydrazones and olefins as neurokinin antagonists
SCHERING CORP70 citations95
US7642272B2Jan 5, 2010
Cannabinoid receptor ligands
SCHERING CORP48 citations94
US7524842B2Apr 28, 2009
Compounds for the treatment of inflammatory disorders
SCHERING CORP19 citations92
US7504424B2Mar 17, 2009
Compounds for the treatment of inflammatory disorders
SCHERING CORP24 citations92
US7488745B2Feb 10, 2009
Compounds for the treatment of inflammatory disorders
SCHERING CORP23 citations92
US7482370B2Jan 27, 2009
Compounds for the treatment of inflammatory disorders
SCHERING CORP20 citations92
US5840725ANov 24, 1998
Substituted oximes, hydrazones and olefins as neurokinin antagonists
SCHERING CORP26 citations91
US7750158B2Jul 6, 2010
Cannabinoid receptor ligands
SCHERING CORP42 citations90
US7781437B2Aug 24, 2010
Substituted heterocyclic compounds with CXCR3 antagonist activity
SCHERING CORP12 citations84
US7763616B2Jul 27, 2010
Piperazine-piperidines with CXCR3 antagonist activity
SCHERING CORP10 citations84
US7687527B2Mar 30, 2010
Compounds for the treatment of inflammatory disorders
SCHERING CORP8 citations84
US7507767B2Mar 24, 2009
Cannabinoid receptor ligands
SCHERING CORP8 citations84
US7217732B2May 15, 2007
Cannabinoid receptor agonists
SCHERING CORP20 citations84
US7071213B2Jul 4, 2006
Cannabinoid receptor ligands
SCHERING CORP16 citations84
US7067539B2Jun 27, 2006
Cannabinoid receptor ligands
SCHERING CORP18 citations84
US7868005B2Jan 11, 2011
Pyrazinyl substituted piperazine-piperidines with CXCR3 antagonist activity
SCHERING CORP9 citations83
US7683085B2Mar 23, 2010
Compounds for the treatment of inflammatory disorders
SCHERING CORP6 citations74
US7879890B2Feb 1, 2011
Compounds for the treatment of inflammatory disorders
SCHERING CORP6 citations73
US7772263B2Aug 10, 2010
Compounds for the treatment of inflammatory disorders
SCHERING CORP7 citations73
US7718702B2May 18, 2010
Cannabinoid receptor ligands
SCHERING CORP5 citations62
US7683088B2Mar 23, 2010
Compounds for the treatment of inflammatory disorders
SCHERING CORP1 citations62
US7645774B2Jan 12, 2010
Cannabinoid receptor ligands
SCHERING CORP0 citations52
US7253189B2Aug 7, 2007
Cannabinoid receptor ligands
SCHERING CORP2 citations52